Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Cash & Current Investments: 2015-2025

Historic Cash & Current Investments for Niagen Bioscience (NAGE) over the last 10 years, with Sep 2025 value amounting to $64.3 million.

  • Niagen Bioscience's Cash & Current Investments rose 98.44% to $64.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $225.0 million, marking a year-over-year increase of 95.39%. This contributed to the annual value of $44.7 million for FY2024, which is 63.44% up from last year.
  • Latest data reveals that Niagen Bioscience reported Cash & Current Investments of $64.3 million as of Q3 2025, which was up 6.31% from $60.5 million recorded in Q2 2025.
  • Niagen Bioscience's Cash & Current Investments' 5-year high stood at $64.3 million during Q3 2025, with a 5-year trough of $13.3 million in Q3 2022.
  • Moreover, its 3-year median value for Cash & Current Investments was $27.9 million (2024), whereas its average is $37.9 million.
  • Per our database at Business Quant, Niagen Bioscience's Cash & Current Investments soared by 228.48% in 2021 and then crashed by 59.94% in 2022.
  • Over the past 5 years, Niagen Bioscience's Cash & Current Investments (Quarterly) stood at $28.2 million in 2021, then decreased by 27.56% to $20.4 million in 2022, then spiked by 33.68% to $27.3 million in 2023, then spiked by 63.44% to $44.7 million in 2024, then spiked by 98.44% to $64.3 million in 2025.
  • Its last three reported values are $64.3 million in Q3 2025, $60.5 million for Q2 2025, and $55.6 million during Q1 2025.